Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

被引：30
作者：
Patel, Jai N. [1 ]
机构：
[1] Carolinas HealthCare Syst, Levine Canc Inst, Dept Canc Pharmacol, 1021 Morehead Med Dr,Rm 4336, Charlotte, NC 28204 USA
来源：
PHARMACOGENOMICS & PERSONALIZED MEDICINE | 2016年 / 9卷
关键词：
oncology; personalized; pharmacogenetics; germline; somatic; DNA; biomarker; CELL LUNG-CANCER; ELECTRONIC HEALTH RECORDS; MICROSATELLITE INSTABILITY; THIOPURINE METHYLTRANSFERASE; CLINICAL IMPLEMENTATION; GENETIC-POLYMORPHISM; 1ST-LINE TREATMENT; COLORECTAL-CANCER; RESISTANCE; GENOTYPE;
D O I：
10.2147/PGPM.S62918
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cancer pharmacogenomics is an evolving landscape and has the potential to significantly impact cancer care and precision medicine. Harnessing and understanding the genetic code of both the patient (germline) and the tumor (somatic) provides the opportunity for personalized dose and therapy selection for cancer patients. While germline DNA is useful in understanding the pharmacokinetic and pharmacodynamic disposition of a drug, somatic DNA is particularly useful in identifying drug targets and predicting drug response. Molecular profiling of somatic DNA has resulted in the current breadth of targeted therapies available, expanding the armamentarium to battle cancer. This review provides an update on cancer pharmacogenomics and genomics-based medicine, challenges in applying pharmacogenomics to the clinical setting, and patient perspectives on the use of pharmacogenomics to personalize cancer therapy.
引用
收藏
页码：65 / 77
页数：13
相关论文
共 87 条
[1]   Rapid-Learning System for Cancer Care [J].
Abernethy, Amy P. ;
Etheredge, Lynn M. ;
Ganz, Patricia A. ;
Wallace, Paul ;
German, Robert R. ;
Neti, Chalapathy ;
Bach, Peter B. ;
Murphy, Sharon B. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4268-4274
[2]   Circulating Tumor Cells: Liquid Biopsy of Cancer [J].
Alix-Panabieres, Catherine ;
Pantel, Klaus .
CLINICAL CHEMISTRY, 2013, 59 (01) :110-118
[3]  
[Anonymous], PUR
[4]  
[Anonymous], 2015, Table of Pharmacogenomic Biomarkers in Drug Labels
[5]  
[Anonymous], HDB RES NOVEL APPROA
[6]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[7]  
Bixby Dale, 2009, Hematology Am Soc Hematol Educ Program, P461, DOI 10.1182/asheducation-2009.1.461
[8]   Genomic Testing in Cancer Patient Knowledge, Attitudes, and Expectations [J].
Blanchette, Phillip S. ;
Spreafico, Anna ;
Miller, Fiona A. ;
Chan, Kelvin ;
Bytautas, Jessica ;
Kang, Steve ;
Bedard, Philippe L. ;
Eisen, Andrea ;
Potanina, Larissa ;
Holland, Jack ;
Kamel-Reid, Suzanne ;
McPherson, John D. ;
Razak, Albiruni R. ;
Siu, Lillian L. .
CANCER, 2014, 120 (19) :3066-3073
[9]   Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment [J].
Buettner, Reinhard ;
Wolf, Juergen ;
Thomas, Roman K. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15) :1858-1865
[10]   Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents [J].
Califano, Raffaele ;
Morgillo, Floriana ;
De Mello, Ramon Andrade ;
Mountzios, Giannis .
ANNALS OF TRANSLATIONAL MEDICINE, 2015, 3 (06)
123456789